Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 245 participants.

Also called NCT03060980

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 245 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03060980
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03060980. Randomized; no masking; primary purpose treatment. Start 2017-03-03 (actual); primary completion 2018-01-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
ITCA 650 20/60 mcg/day
Intervention (Drug)
Empagliflozin (oral)
Intervention (Drug)
Glimepiride (oral)
Lead sponsor
Intarcia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct03060980
Content hash
495e4212b88adf7d533fb12edac92723e1e3de2520da93c3642be1562eee3e64